Literature DB >> 30190963

Rationale of transcatheter intra-arterial therapies of hepatic cancers.

Ryan M Hickey1, Robert J Lewandowski1, Riad Salem1.   

Abstract

Transcatheter, intra-arterial therapies for primary and metastatic hepatic malignancies comprise angiographically guided procedures that provide for the administration of tumoricidal agents directly to liver tumors. These locoregional therapies have demonstrated encouraging clinical outcomes for liver tumors that are otherwise not amenable or not responsive to standard surgical or systemic treatments. This article provides a review of transcatheter therapies for hepatic cancers and reported clinical outcomes.

Entities:  

Year:  2014        PMID： 30190963      PMCID： PMC6095317          DOI： 10.2217/hep.14.11

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN： 2045-0923


  72 in total

1.  Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma.

Authors:  H K Kim; Y H Chung; B C Song; S H Yang; H K Yoon; E Yu; K B Sung; Y S Lee; S G Lee; D J Suh
Journal:  J Clin Gastroenterol       Date:  2001 May-Jun       Impact factor: 3.062

Review 2.  Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria.

Authors:  Daniel B Brown; Jennifer E Gould; Debra A Gervais; S Nahum Goldberg; Ravi Murthy; Steven F Millward; William S Rilling; Jean-Francois S Geschwind; Riad Salem; Suresh Vedantham; John F Cardella; Michael C Soulen
Journal:  J Vasc Interv Radiol       Date:  2007-12       Impact factor: 3.464

3.  Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.

Authors:  Riad Salem; Robert J Lewandowski; Laura Kulik; Edward Wang; Ahsun Riaz; Robert K Ryu; Kent T Sato; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Saad M Ibrahim; Seanthan Senthilnathan; Talia Baker; Vanessa L Gates; Bassel Atassi; Steven Newman; Khairuddin Memon; Richard Chen; Robert L Vogelzang; Albert A Nemcek; Scott A Resnick; Howard B Chrisman; James Carr; Reed A Omary; Michael Abecassis; Al B Benson; Mary F Mulcahy
Journal:  Gastroenterology       Date:  2010-10-30       Impact factor: 22.682

4.  Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

Authors:  Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

5.  Transarterial chemoembolisation (TACE) with gemcitabine: phase II study in patients with liver metastases of breast cancer.

Authors:  Katrin Eichler; Silke Jakobi; Tatjana Gruber-Rouh; Renate Hammerstingl; Thomas J Vogl; Stephan Zangos
Journal:  Eur J Radiol       Date:  2013-09-01       Impact factor: 3.528

6.  Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report.

Authors:  T Konno; H Maeda; K Iwai; S Tashiro; S Maki; T Morinaga; M Mochinaga; T Hiraoka; I Yokoyama
Journal:  Eur J Cancer Clin Oncol       Date:  1983-08

7.  Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors.

Authors:  Sanjay Gupta; Agop Y Bedikian; Judy Ahrar; Joe Ensor; Kamran Ahrar; David C Madoff; Michael J Wallace; Ravi Murthy; Alda Tam; Patrick Hwu
Journal:  Am J Clin Oncol       Date:  2010-10       Impact factor: 2.339

8.  Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization.

Authors:  Eleni Liapi; Jean-Francois Geschwind; Josephina A Vossen; Manon Buijs; Christos S Georgiades; David A Bluemke; Ihab R Kamel
Journal:  AJR Am J Roentgenol       Date:  2008-01       Impact factor: 3.959

9.  Intrahepatic biloma formation (bile duct necrosis) after transcatheter arterial chemoembolization.

Authors:  Ichiro Sakamoto; Soji Iwanaga; Kenji Nagaoki; Yojiro Matsuoka; Kazuto Ashizawa; Masataka Uetani; Toshio Fukuda; Tomoaki Okimoto; Sadayuki Okudaira; Katsuhisa Omagari; Kuniaki Hayashi; Naofumi Matsunaga
Journal:  AJR Am J Roentgenol       Date:  2003-07       Impact factor: 3.959

10.  Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Authors:  Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-12       Impact factor: 2.740
View more
  1 in total

Review 1.  Making the Case: Intra-arterial Therapy for Less Common Metastases.

Authors:  Andrew C Gordon; Omar M Uddin; Ahsun Riaz; Riad Salem; Robert J Lewandowski
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.